Head-to-head · WeighScore
HealthSource vs Maves
The verdict
Maves takes it — 71.8/100 to 71.2/100, but only just.
Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with… HealthSource is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | HealthSource | Maves |
|---|---|---|
| WeighScore | 71.2/100 | 71.8/100 |
| Grade | C | C |
| Scorecard rank | #97 | #88 |
| Semaglutide | $199/mo (all doses, compounded) | $99/mo (starting dose, first-month rate, compounded) |
| Tirzepatide | $299/mo (all doses, compounded) | Not disclosed |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #97 · C
Strengths
- Three GLP-1 options: compounded semaglutide injection, tirzepatide injection, and oral sublingual tirzepatide
- 24/7 access to care team via HIPAA-compliant platform with unlimited physician messaging
- Every program covers the cost of medication, supplies, and telehealth visits — no separate pharmacy fee
- Subscription auto-refund if monthly reassessment is not completed
- Available in all 50 US states including Alaska and Hawaii with 3–5 day shipping
Where it loses points
- No physician names or clinical leadership disclosed on public pages
- No LegitScript certification found
- 503A partner pharmacy not named — less transparent than providers disclosing their 503B pharmacy
- Labs not mentioned on any product page — baseline bloodwork protocol unknown
- WooCommerce e-commerce storefront may feel more transactional than clinical
Graded #88 · C
Strengths
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
- All 50 states covered, stated explicitly
- Both brand (Maves) and parent (Homera Health) disclosed for accountability
Where it loses points
- 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
- Tirzepatide pricing not stated on the homepage — only listed as an offering
- Named medical director / clinical leadership not disclosed
- Refund and cancellation policy not detailed publicly
- Corporate address and arbitration venue not disclosed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.